Yusuke Nakamura to Antibodies, Monoclonal
This is a "connection" page, showing publications Yusuke Nakamura has written about Antibodies, Monoclonal.
Connection Strength
0.641
-
Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016 Jul; 107(7):1055-8.
Score: 0.363
-
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
Score: 0.088
-
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008 Feb; 99(2):432-40.
Score: 0.051
-
Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006 Nov; 97(11):1191-7.
Score: 0.046
-
a-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018 Jul; 109(7):2302-2309.
Score: 0.026
-
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
Score: 0.026
-
In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunol Immunother. 2012 Aug; 61(8):1211-20.
Score: 0.017
-
Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med. 2009 Jul; 23(5):479-85.
Score: 0.014
-
Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer. Int J Oncol. 2005 Dec; 27(6):1483-7.
Score: 0.011